SARTORELLO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.586
EU - Europa 175
AS - Asia 146
AF - Africa 1
OC - Oceania 1
Totale 1.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.584
CN - Cina 89
VN - Vietnam 50
SE - Svezia 37
FI - Finlandia 32
GB - Regno Unito 29
IT - Italia 22
DE - Germania 18
NL - Olanda 12
UA - Ucraina 11
BE - Belgio 4
FR - Francia 3
IE - Irlanda 3
IN - India 3
CA - Canada 2
RO - Romania 2
TR - Turchia 2
AT - Austria 1
HU - Ungheria 1
JP - Giappone 1
NZ - Nuova Zelanda 1
PH - Filippine 1
UG - Uganda 1
Totale 1.909
Salva come PNG Salva come JPEG
Città #
Fairfield 307
Ashburn 155
Chandler 154
Houston 128
Cambridge 115
Woodbridge 114
Seattle 104
Ann Arbor 84
Wilmington 76
Jacksonville 56
Dong Ket 50
Princeton 40
Beijing 26
San Diego 25
Nanjing 17
Medford 16
Washington 15
Roxbury 12
Helsinki 10
Padova 10
Boardman 8
New York 8
Changsha 7
Des Moines 6
Hebei 6
Shenyang 6
Hefei 5
London 5
Borås 4
Norwalk 4
Waanrode 4
Dublin 3
Kharkiv 3
Redwood City 3
Tianjin 3
Tivoli 3
Florence 2
Guangzhou 2
Indiana 2
Istanbul 2
Milan 2
Pune 2
Auckland 1
Budapest 1
Cormeilles-en-Parisis 1
Dallas 1
Dearborn 1
Delhi 1
Kampala 1
Kilburn 1
Malo 1
Manila 1
Ningbo 1
Rockville 1
Shanghai 1
Simi Valley 1
Southwark 1
Stockholm 1
Taiyuan 1
Tolbert 1
Totale 1.622
Salva come PNG Salva come JPEG
Nome #
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 116
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 107
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 104
Higher and lower active circulating VWF levels: different facets of von Willebrand disease 90
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 90
Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke 88
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 88
A novel von Willebrand factor mutation (11372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis 85
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 79
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 78
Which assay is the most suitable to investigate von Willebrand factor functional activity? 74
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease. 74
Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 73
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 72
Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization. 70
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. 69
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 67
Combined exon skipping and cryptic splice activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 65
Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. 65
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 65
Haplotypes of Von Willebrand factor promoter predict thrombotic risk in Cushing's syndrome 59
Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. 58
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 58
Identifying carriers of type 2N von Willebrand disease: procedures and significance. 38
Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. 36
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 28
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 23
Totale 1.919
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.836
article - articoli 6.692
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019206 0 0 0 0 0 0 0 0 0 36 90 80
2019/2020407 69 17 5 31 47 28 42 54 48 28 21 17
2020/2021299 13 12 4 32 12 30 13 28 37 17 26 75
2021/2022364 16 29 70 18 6 29 16 43 10 6 53 68
2022/2023297 56 38 7 30 57 31 2 18 37 3 18 0
2023/2024172 2 27 32 17 29 38 20 3 1 3 0 0
Totale 1.919